An investigation for investors in United Therapeutics Corporation (NASDAQ:UTHR) shares over potential securities laws violations by United Therapeutics was announced and NASDAQ:UTHR stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 08/08/2017 -- An investigation on behalf of investors of United Therapeutics Corporation (NASDAQ:UTHR) shares over potential securities laws violations by United Therapeutics and certain of its directors and officers in connection with certain financial statements was announced.
Investors who purchased shares of United Therapeutics Corporation (NASDAQ:UTHR), have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm focuses on whether a series of statements by United Therapeutics regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On July 27, 2017, United Therapeutics Corporation disclosed that it has set aside $210 million in connection to a possible settlement with the U.S. Department of Justice ("DOJ") whether the company's contributions to patient-assistance charity groups violate federal laws against kickbacks and false claims. The DOJ previously subpoenaed United Therapeutics Corporation for information about its contributions to non-profit organizations that provide financial assistance to patients with out-of-pocket drug costs. United Therapeutics Corporation stated that it expects any settlement would also include a corporate integrity agreement, and the company may incur significant future costs to comply with that agreement. Shares of United Therapeutics Corporation (NASDAQ:UTHR) declined to as low as $123.05 per share on July 27, 2017.
On August 7, 2017, NASDAQ:UTHR shares closed at $135.46 per share.
Those who purchased shares of United Therapeutics Corporation have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels